PetVivo Reports Fiscal Q2 2026 Results with Revenues up 50%

Core Insights - PetVivo Holdings, Inc. reported a 51% increase in revenues for the second quarter of fiscal year 2026, totaling $303,000, driven by the introduction of the new product line PrecisePRP and expansion into the companion animal market [7][19][21] - The company has successfully entered the European market through a partnership with Nupsala Group, enhancing its distribution capabilities [6][16] - PetVivo's strategic collaborations, including with Digital Landia and Commonwealth Markets, are expected to enhance product adoption and market presence [10][17][18] Fiscal Q2 Financial Highlights - Revenues increased to $303,000, up 51% from the same quarter last year, marking a record for the second fiscal quarter [7][19] - Gross profit rose to $220,000, with a gross margin of 72.6%, an improvement from 63.8% in the previous quarter [20] - Operating loss increased to $2.1 million, while net loss rose to $3.0 million, reflecting increased sales and marketing expenses [21][22] Fiscal Q2 Operational Highlights - The company engaged additional distributors to support domestic and international expansion, with national distributor network sales increasing by 35% [7][19] - PetVivo's flagship product, Spryng with OsteoCushion Technology, has been adopted by over 1,200 veterinary clinics across the U.S. [17] - The company launched three new continuing education courses for veterinary professionals to enhance expertise in osteoarthritis and regenerative modalities [13] Strategic Partnerships and Innovations - A strategic partnership with Digital Landia aims to integrate AI technology into PetVivo's veterinary products, potentially reducing client acquisition costs significantly [10][18] - The collaboration with Commonwealth Markets has led to the integration of Spryng and PrecisePRP into care protocols for thoroughbred horses [17] - Ongoing research with PiezoBioMembrane is focused on developing biodegradable piezoelectric materials for regenerative applications [12][15] Financial Outlook - Management anticipates continued record growth for the full fiscal year ending March 31, 2026, driven by the expansion of Spryng and PrecisePRP [24][25] - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing significant growth opportunities for PetVivo [18]